David Frazier Jarrard

Title: David Frazier Jarrard: Innovator in Prostate Cancer Research

Introduction

David Frazier Jarrard is a prominent inventor based in Madison, WI (US). He has made significant contributions to the field of prostate cancer research, holding a total of 9 patents. His work focuses on developing innovative methods for detecting prostate cancer through genomic analysis.

Latest Patents

Among his latest patents is a groundbreaking method titled "Unbiased DNA methylation markers define an extensive field defect in histologically normal prostate tissues associated with prostate cancer: new biomarkers for men with prostate cancer." This method involves obtaining genomic DNA from a human subject and quantifying methylation in specific target regions. Significant methylation changes indicate the presence of prostate cancer or a prostate cancer field defect. Another notable patent under the same title outlines a similar method, emphasizing the determination of methylation status in various target regions, which also serves as an indicator of prostate cancer.

Career Highlights

David has worked with esteemed organizations such as the Wisconsin Alumni Research Foundation and the Medical College of Wisconsin, Inc. His research has been pivotal in advancing the understanding of prostate cancer and developing new diagnostic tools.

Collaborations

Throughout his career, David has collaborated with notable colleagues, including Bing Yang and Peter LaViolette. These partnerships have contributed to the success of his research and innovations.

Conclusion

David Frazier Jarrard's work in prostate cancer research exemplifies the impact of innovative thinking in medicine. His patents and collaborations continue to pave the way for advancements in cancer diagnostics and treatment.